Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
2024

Testing for STK11 and KEAP1 Mutations in Advanced Lung Cancer

Sample size: 3745 publication Evidence: moderate

Author Information

Author(s): Michelle Shiller, Melissa Johnson, Robert Auber, Sandip Pravin Patel

Primary Institution: Baylor University Medical Center

Hypothesis

What is the impact of STK11 and KEAP1 mutations on treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC)?

Conclusion

Patients with STK11 and KEAP1 mutations have poorer outcomes when treated with standard therapies for advanced NSCLC.

Supporting Evidence

  • STK11 mutations were found in 8.6% and KEAP1 mutations in 5.7% of patients.
  • Patients with STK11 or KEAP1 mutations had worse overall survival compared to those without these mutations.
  • Routine biomarker testing is recommended for all patients with NSCLC to guide treatment decisions.

Takeaway

Some patients with lung cancer have mutations that make their disease harder to treat, and knowing about these mutations can help doctors choose better treatments.

Methodology

The study analyzed tumor samples from 3,745 patients with NSCLC, using various biomarker testing methodologies to identify mutations.

Limitations

The study's findings may not be generalizable due to the specific population analyzed and the focus on certain mutations.

Participant Demographics

The study included patients with NSCLC of any stage, with a focus on those undergoing routine pathological subtyping.

Digital Object Identifier (DOI)

10.3389/fonc.2024.1459737

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication